Viz.ai Receives FDA 510(k) Clearance for Automated RV/LV Analysis Algorithm

Part of the Viz PE Solution, new algorithm flags key patient risk indicator of pulmonary embolism severity. SAN FRANCISCO – September 1, 2022 - Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for an automated RV/LV ratio algorithm, a seamless new component of the Viz PE Solution. Diagnosis and care coordination for patients suffering from PE requires fast multi-disciplinary communication for risk stratification and decision making. With this clearance, the Viz PE Solution now includes both detection of clot in the lungs and degree of strain on the right heart. This will enable clinicians to quickly triage patients and treat them appropriately, by providing a powerful tool for early detection and risk stratification.